{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:20Z","timestamp":1786979900380,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K24CA201543-01"],"award-info":[{"award-number":["K24CA201543-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1U01AI156189-01"],"award-info":[{"award-number":["1U01AI156189-01"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UT Southwestern Cancer Biology Training Grant","award":["5T32CA124334-13"],"award-info":[{"award-number":["5T32CA124334-13"]}]},{"name":"Harold C. Simmons Comprehensive Cancer Center Data Sciences Shared Resource","award":["1P30 CA 142543-03"],"award-info":[{"award-number":["1P30 CA 142543-03"]}]},{"name":"UT Southwestern Center for Translational Medicine","award":["UL1TR001105"],"award-info":[{"award-number":["UL1TR001105"]}]},{"name":"Burroughs Wellcome Fund Physician-Scientist Institutional Award."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thyroid dysfunction is among the most common autoimmune diseases and immune checkpoint inhibitor (ICI)-induced immune-related adverse events (irAE). We determined the association between longitudinal thyroid function and clinical outcomes in patients treated with ICI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We identified all patients treated with ICI at UT Southwestern Medical Center from January 1, 2011, through December 31, 2020. We defined normal thyroid stimulating hormone (TSH) and free thyroxine (FT4) levels according to institutional reference range. We defined clinical thyroid dysfunction using established criteria incorporating labs and treatment. We determined the association between thyroid function and overall survival (OS) using Kaplan\u2013Meier curves, log-rank tests, and multivariate Cox proportional hazards model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 1781 patients were included in analyses, of whom 381 (21%) had abnormal baseline TSH. Patients with abnormal baseline TSH were more likely to be female, have kidney cancer, and initiate levothyroxine after ICI initiation (all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Patients with abnormal baseline TSH had inferior OS (median 16 vs 27\u00a0months;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). Among patients with normal baseline TSH, those who had abnormal TSH after ICI initiation had improved OS (median 41 vs 22\u00a0months;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). In a multivariate Cox model, abnormal baseline TSH was associated with worse OS (HR 1.62; 95% CI, 1.30\u20132.02;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), while initiation of levothyroxine after ICI initiation was associated with improved OS (HR 0.62; 95% CI, 0.44\u20130.88;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.008).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ICI-induced thyroid dysfunction is associated with improved survival, although abnormal TSH prior to ICI initiation is associated with inferior survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Precis<\/jats:title>\n                    <jats:p>Thyroid abnormalities occur commonly in the general population and as immunotherapy toxicities. We found that immunotherapy-induced thyroid dysfunction is associated with better survival, but pre-existing thyroid abnormalities convey worse outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00262-022-03151-2","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T08:09:51Z","timestamp":1643011791000},"page":"2169-2181","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors"],"prefix":"10.1007","volume":"71","author":[{"given":"Mitchell S.","family":"von Itzstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrit S.","family":"Gonugunta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Sheffield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadia","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farjana J.","family":"Fattah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donglu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,24]]},"reference":[{"key":"3151_CR1","doi-asserted-by":"crossref","unstructured":"Wright JJ, Powers AC, Johnson DB (2021) Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol","DOI":"10.1038\/s41574-021-00484-3"},{"issue":"1","key":"3151_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23\u201334","journal-title":"N Engl J Med"},{"issue":"7","key":"3151_CR3","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s40618-018-0984-z","volume":"42","author":"RM Ruggeri","year":"2019","unstructured":"Ruggeri RM, Campenni A, Giuffrida G, Trimboli P, Giovanella L, Trimarchi F et al (2019) Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know). J Endocrinol Invest 42(7):745\u2013756","journal-title":"J Endocrinol Invest"},{"key":"3151_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","volume":"58","author":"M Sznol","year":"2017","unstructured":"Sznol M, Postow MA, Davies MJ, Pavlick AC, Plimack ER, Shaheen M et al (2017) Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treat Rev 58:70\u201376","journal-title":"Cancer Treat Rev"},{"issue":"21","key":"3151_CR5","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","volume":"30","author":"JS Weber","year":"2012","unstructured":"Weber JS, Kahler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30(21):2691\u20132697","journal-title":"J Clin Oncol"},{"issue":"7","key":"3151_CR6","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","volume":"35","author":"JS Weber","year":"2017","unstructured":"Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J et al (2017) Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 35(7):785\u2013792","journal-title":"J Clin Oncol"},{"issue":"34","key":"3151_CR7","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1200\/JCO.2016.72.1167","volume":"35","author":"M Sznol","year":"2017","unstructured":"Sznol M, Ferrucci PF, Hogg D, Atkins MB, Wolter P, Guidoboni M et al (2017) Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. J Clin Oncol 35(34):3815\u20133822","journal-title":"J Clin Oncol"},{"issue":"12","key":"3151_CR8","doi-asserted-by":"publisher","first-page":"T331","DOI":"10.1530\/ERC-17-0358","volume":"24","author":"P Cukier","year":"2017","unstructured":"Cukier P, Santini FC, Scaranti M, Hoff AO (2017) Endocrine side effects of cancer immunotherapy. Endocr Relat Cancer 24(12):T331\u2013T347","journal-title":"Endocr Relat Cancer"},{"issue":"17","key":"3151_CR9","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol 36(17):1714\u20131768","journal-title":"J Clin Oncol"},{"issue":"5","key":"3151_CR10","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1530\/EJE-14-0481","volume":"171","author":"A Carle","year":"2014","unstructured":"Carle A, Pedersen IB, Knudsen N, Perrild H, Ovesen L, Laurberg P (2014) Hypothyroid symptoms and the likelihood of overt thyroid failure: a population-based case-control study. Eur J Endocrinol 171(5):593\u2013602","journal-title":"Eur J Endocrinol"},{"issue":"10101","key":"3151_CR11","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/S0140-6736(17)30703-1","volume":"390","author":"L Chaker","year":"2017","unstructured":"Chaker L, Bianco AC, Jonklaas J, Peeters RP (2017) Hypothyroidism. Lancet 390(10101):1550\u20131562","journal-title":"Lancet"},{"issue":"2","key":"3151_CR12","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1210\/jcem.87.2.8182","volume":"87","author":"JG Hollowell","year":"2002","unstructured":"Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA et al (2002) Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 87(2):489\u2013499","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"3151_CR13","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1210\/jc.2013-2409","volume":"99","author":"A Garmendia Madariaga","year":"2014","unstructured":"Garmendia Madariaga A, Santos Palacios S, Guillen-Grima F, Galofre JC (2014) The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clin Endocrinol Metab 99(3):923\u2013931","journal-title":"J Clin Endocrinol Metab"},{"key":"3151_CR14","doi-asserted-by":"crossref","unstructured":"Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB et al (2021) Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 9(6)","DOI":"10.1136\/jitc-2021-002435"},{"key":"3151_CR15","doi-asserted-by":"crossref","unstructured":"Cortellini A, Chiari R, Ricciuti B, Metro G, Perrone F, Tiseo M et al (2019) Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients. Clin Lung Cancer","DOI":"10.1016\/j.cllc.2019.02.006"},{"issue":"1","key":"3151_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s40425-019-0579-z","volume":"7","author":"E Verzoni","year":"2019","unstructured":"Verzoni E, Carteni G, Cortesi E, Giannarelli D, De Giglio A, Sabbatini R et al (2019) Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program. J Immunother Cancer 7(1):99","journal-title":"J Immunother Cancer"},{"key":"3151_CR17","doi-asserted-by":"crossref","unstructured":"Peiro I, Palmero R, Iglesias P, Diez JJ, Simo-Servat A, Marin JA et al (2019) Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes. Endocrine","DOI":"10.1007\/s12020-019-01871-7"},{"issue":"3","key":"3151_CR18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/annonc\/mdw640","volume":"28","author":"JC Osorio","year":"2017","unstructured":"Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D et al (2017) Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 28(3):583\u2013589","journal-title":"Ann Oncol"},{"key":"3151_CR19","doi-asserted-by":"crossref","unstructured":"Kotwal A, Kottschade L, Ryder M (2020) PD-L1 Inhibitor-induced thyroiditis is associated with better overall survival in cancer patients. Thyroid","DOI":"10.1089\/thy.2019.0250"},{"issue":"18","key":"3151_CR20","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.1158\/1078-0432.CCR-21-0921","volume":"27","author":"J Luo","year":"2021","unstructured":"Luo J, Martucci VL, Quandt Z, Groha S, Murray MH, Lovly CM et al (2021) Immunotherapy-mediated thyroid dysfunction: genetic risk and impact on outcomes with PD-1 blockade in non-small cell lung cancer. Clin Cancer Res 27(18):5131\u20135140","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3151_CR21","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1038\/s41467-021-23661-4","volume":"12","author":"Z Khan","year":"2021","unstructured":"Khan Z, Hammer C, Carroll J, Di Nucci F, Acosta SL, Maiya V et al (2021) Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade. Nat Commun 12(1):3355","journal-title":"Nat Commun"},{"issue":"6","key":"3151_CR22","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S2213-8587(18)30371-1","volume":"7","author":"J Jonklaas","year":"2019","unstructured":"Jonklaas J, Razvi S (2019) Reference intervals in the diagnosis of thyroid dysfunction: treating patients not numbers. Lancet Diabetes Endocrinol 7(6):473\u2013483","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"3151_CR23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1159\/000438750","volume":"4","author":"B Biondi","year":"2015","unstructured":"Biondi B, Bartalena L, Cooper DS, Hegedus L, Laurberg P, Kahaly GJ (2015) The 2015 European thyroid association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism. Eur Thyroid J 4(3):149\u2013163","journal-title":"Eur Thyroid J"},{"issue":"9","key":"3151_CR24","doi-asserted-by":"publisher","first-page":"e1911519","DOI":"10.1001\/jamanetworkopen.2019.11519","volume":"2","author":"D Hsiehchen","year":"2019","unstructured":"Hsiehchen D, Watters MK, Lu R, Xie Y, Gerber DE (2019) Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors. JAMA Netw Open 2(9):e1911519","journal-title":"JAMA Netw Open"},{"issue":"5","key":"3151_CR25","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrendo.2018.18","volume":"14","author":"PN Taylor","year":"2018","unstructured":"Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM et al (2018) Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol 14(5):301\u2013316","journal-title":"Nat Rev Endocrinol"},{"key":"3151_CR26","unstructured":"Stone MB, Wallace RB (eds) (2003) Medicare coverage of routine screening for thyroid dysfunction. Washington (DC)"},{"issue":"12","key":"3151_CR27","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1089\/thy.2006.0235","volume":"17","author":"Y Aoki","year":"2007","unstructured":"Aoki Y, Belin RM, Clickner R, Jeffries R, Phillips L, Mahaffey KR (2007) Serum TSH and total T4 in the United States population and their association with participant characteristics: National Health and Nutrition Examination Survey (NHANES 1999\u20132002). Thyroid 17(12):1211\u20131223","journal-title":"Thyroid"},{"issue":"15","key":"3151_CR28","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1001\/jama.2013.285606","volume":"311","author":"DS McLeod","year":"2014","unstructured":"McLeod DS, Caturegli P, Cooper DS, Matos PG, Hutfless S (2014) Variation in rates of autoimmune thyroid disease by race\/ethnicity in US military personnel. JAMA 311(15):1563\u20131565","journal-title":"JAMA"},{"issue":"21","key":"3151_CR29","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad G, Helmink BA, Sharma P, Wargo JA (2021) Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 184(21):5309\u20135337","journal-title":"Cell"},{"issue":"14","key":"3151_CR30","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T et al (2021) Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 384(14):1289\u20131300","journal-title":"N Engl J Med"},{"key":"3151_CR31","doi-asserted-by":"crossref","unstructured":"Brody HM, Macherla SM, Bulumulle A, Namireddy P, Cherry CR (2020) The real-world incidence of immunotherapy-related thyroid dysfunction: a retrospective analysis of a single center's experience over five years. J Clin Oncol 38(5_suppl):98\u201398. (Published online February 04, 2020)","DOI":"10.1200\/JCO.2020.38.5_suppl.98"},{"issue":"12","key":"3151_CR32","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1001\/jama.2010.1361","volume":"304","author":"N Rodondi","year":"2010","unstructured":"Rodondi N, den Elzen WP, Bauer DC, Cappola AR, Razvi S, Walsh JP et al (2010) Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA 304(12):1365\u20131374","journal-title":"JAMA"},{"issue":"4","key":"3151_CR33","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.amjmed.2015.11.027","volume":"129","author":"A Grossman","year":"2016","unstructured":"Grossman A, Weiss A, Koren-Morag N, Shimon I, Beloosesky Y, Meyerovitch J (2016) Subclinical thyroid disease and mortality in the elderly: a retrospective cohort study. Am J Med 129(4):423\u2013430","journal-title":"Am J Med"},{"issue":"21","key":"3151_CR34","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1001\/jama.292.21.2591","volume":"292","author":"J Gussekloo","year":"2004","unstructured":"Gussekloo J, van Exel E, de Craen AJ, Meinders AE, Frolich M, Westendorp RG (2004) Thyroid status, disability and cognitive function, and survival in old age. JAMA 292(21):2591\u20132599","journal-title":"JAMA"},{"key":"3151_CR35","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ejim.2017.11.010","volume":"50","author":"A Grossman","year":"2018","unstructured":"Grossman A, Feldhamer I, Meyerovitch J (2018) Treatment with levothyroxin in subclinical hypothyroidism is associated with increased mortality in the elderly. Eur J Internal Med 50:65\u201368","journal-title":"Eur J Internal Med"},{"issue":"4","key":"3151_CR36","doi-asserted-by":"publisher","first-page":"e0122955","DOI":"10.1371\/journal.pone.0122955","volume":"10","author":"FY Tseng","year":"2015","unstructured":"Tseng FY, Lin WY, Li CI, Li TC, Lin CC, Huang KC (2015) Subclinical hypothyroidism is associated with increased risk for cancer mortality in adult Taiwanese-a 10 years population-based cohort. PLoS ONE 10(4):e0122955","journal-title":"PLoS ONE"},{"key":"3151_CR37","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fendo.2012.00008","volume":"3","author":"SM Wajner","year":"2012","unstructured":"Wajner SM, Maia AL (2012) New insights toward the acute non-thyroidal illness syndrome. Front Endocrinol (Lausanne) 3:8","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"3151_CR38","doi-asserted-by":"publisher","first-page":"e34442","DOI":"10.1371\/journal.pone.0034442","volume":"7","author":"N Eriksson","year":"2012","unstructured":"Eriksson N, Tung JY, Kiefer AK, Hinds DA, Francke U, Mountain JL et al (2012) Novel associations for hypothyroidism include known autoimmune risk loci. PLoS ONE 7(4):e34442","journal-title":"PLoS ONE"},{"issue":"2","key":"3151_CR39","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/annonc\/mdw443","volume":"28","author":"AM Menzies","year":"2017","unstructured":"Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ et al (2017) Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 28(2):368\u2013376","journal-title":"Ann Oncol"},{"key":"3151_CR40","doi-asserted-by":"crossref","unstructured":"Brilli L, Danielli R, Campanile M, Secchi C, Ciuoli C, Calabro L et al (2020) Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy. J Endocrinol Invest","DOI":"10.1007\/s40618-020-01480-6"},{"issue":"8","key":"3151_CR41","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1210\/jc.2013-1607","volume":"98","author":"TH Kim","year":"2013","unstructured":"Kim TH, Kim KW, Ahn HY, Choi HS, Won H, Choi Y et al (2013) Effect of seasonal changes on the transition between subclinical hypothyroid and euthyroid status. J Clin Endocrinol Metab 98(8):3420\u20133429","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"3151_CR42","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.4158\/EP14477.RA","volume":"21","author":"JV Hennessey","year":"2015","unstructured":"Hennessey JV (2015) Historical and current perspective in the use of thyroid extracts for the treatment of hypothyroidism. Endocr Pract 21(10):1161\u20131170","journal-title":"Endocr Pract"}],"updated-by":[{"DOI":"10.1007\/s00262-022-03218-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:00:00Z","timestamp":1653091200000}}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03151-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-022-03151-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-022-03151-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T07:04:37Z","timestamp":1660287877000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-022-03151-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,24]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["3151"],"URL":"https:\/\/doi.org\/10.1007\/s00262-022-03151-2","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,24]]},"assertion":[{"value":"17 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00262-022-03218-0","URL":"https:\/\/doi.org\/10.1007\/s00262-022-03218-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}